Cargando…
Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589698/ https://www.ncbi.nlm.nih.gov/pubmed/28903459 http://dx.doi.org/10.18632/oncotarget.20268 |
| _version_ | 1783262387407683584 |
|---|---|
| author | Kim, Hye Ryun Jang, Joung Soon Sun, Jong-Mu Ahn, Myung-Ju Kim, Dong-Wan Jung, Inkyung Lee, Ki Hyeong Kim, Joo-Hang Lee, Dae Ho Kim, Sang-We Cho, Byoung Chul |
| author_facet | Kim, Hye Ryun Jang, Joung Soon Sun, Jong-Mu Ahn, Myung-Ju Kim, Dong-Wan Jung, Inkyung Lee, Ki Hyeong Kim, Joo-Hang Lee, Dae Ho Kim, Sang-We Cho, Byoung Chul |
| author_sort | Kim, Hye Ryun |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5589698 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Impact Journals LLC |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-55896982017-09-12 Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) Kim, Hye Ryun Jang, Joung Soon Sun, Jong-Mu Ahn, Myung-Ju Kim, Dong-Wan Jung, Inkyung Lee, Ki Hyeong Kim, Joo-Hang Lee, Dae Ho Kim, Sang-We Cho, Byoung Chul Oncotarget Correction Impact Journals LLC 2017-08-14 /pmc/articles/PMC5589698/ /pubmed/28903459 http://dx.doi.org/10.18632/oncotarget.20268 Text en Copyright: © 2017 Kim et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| spellingShingle | Correction Kim, Hye Ryun Jang, Joung Soon Sun, Jong-Mu Ahn, Myung-Ju Kim, Dong-Wan Jung, Inkyung Lee, Ki Hyeong Kim, Joo-Hang Lee, Dae Ho Kim, Sang-We Cho, Byoung Chul Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) |
| title | Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) |
| title_full | Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) |
| title_fullStr | Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) |
| title_full_unstemmed | Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) |
| title_short | Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) |
| title_sort | correction: a randomized, phase ii study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (kcsg lu12-01) |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589698/ https://www.ncbi.nlm.nih.gov/pubmed/28903459 http://dx.doi.org/10.18632/oncotarget.20268 |
| work_keys_str_mv | AT kimhyeryun correctionarandomizedphaseiistudyofgefitinibaloneversusnimotuzumabplusgefitinibafterplatinumbasedchemotherapyinadvancednonsmallcelllungcancerkcsglu1201 AT jangjoungsoon correctionarandomizedphaseiistudyofgefitinibaloneversusnimotuzumabplusgefitinibafterplatinumbasedchemotherapyinadvancednonsmallcelllungcancerkcsglu1201 AT sunjongmu correctionarandomizedphaseiistudyofgefitinibaloneversusnimotuzumabplusgefitinibafterplatinumbasedchemotherapyinadvancednonsmallcelllungcancerkcsglu1201 AT ahnmyungju correctionarandomizedphaseiistudyofgefitinibaloneversusnimotuzumabplusgefitinibafterplatinumbasedchemotherapyinadvancednonsmallcelllungcancerkcsglu1201 AT kimdongwan correctionarandomizedphaseiistudyofgefitinibaloneversusnimotuzumabplusgefitinibafterplatinumbasedchemotherapyinadvancednonsmallcelllungcancerkcsglu1201 AT junginkyung correctionarandomizedphaseiistudyofgefitinibaloneversusnimotuzumabplusgefitinibafterplatinumbasedchemotherapyinadvancednonsmallcelllungcancerkcsglu1201 AT leekihyeong correctionarandomizedphaseiistudyofgefitinibaloneversusnimotuzumabplusgefitinibafterplatinumbasedchemotherapyinadvancednonsmallcelllungcancerkcsglu1201 AT kimjoohang correctionarandomizedphaseiistudyofgefitinibaloneversusnimotuzumabplusgefitinibafterplatinumbasedchemotherapyinadvancednonsmallcelllungcancerkcsglu1201 AT leedaeho correctionarandomizedphaseiistudyofgefitinibaloneversusnimotuzumabplusgefitinibafterplatinumbasedchemotherapyinadvancednonsmallcelllungcancerkcsglu1201 AT kimsangwe correctionarandomizedphaseiistudyofgefitinibaloneversusnimotuzumabplusgefitinibafterplatinumbasedchemotherapyinadvancednonsmallcelllungcancerkcsglu1201 AT chobyoungchul correctionarandomizedphaseiistudyofgefitinibaloneversusnimotuzumabplusgefitinibafterplatinumbasedchemotherapyinadvancednonsmallcelllungcancerkcsglu1201 |